A new study published in the Journal of the American Medical Association revealed that a 4-week vancomycin pulse and taper ...

Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive global license agreement with Valneva SE (Nasdaq: ...

A new study from the University of Minnesota Medical School has demonstrated that fecal microbiota transplantation (FMT) can ...

Yesterday Utah officials said the state has 602 measles cases in an outbreak that is ongoing and began last year, with 19 new ...

Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is ...

A 4-week vancomycin pulse and taper regimen may be a safe and effective strategy to delay or prevent Clostridioides difficile ...

An experimental antibiotic called EVG7 has shown promise against gram-positive bacterium Clostridioides difficile, the leading cause of healthcare and antibiotic-associated diarrhea in the US and ...

Non-antibiotic drugs with the greatest observed risks for C. difficile infection were antidiarrheals, analgesics, and ...

A new study from the University of Minnesota Medical School demonstrated that fecal microbiota transplantation (FMT) can rapidly reverse systemic inflammation and improve survival in patients with ...

Highlights include pooled safety findings from Paratek's Phase 3 studies in community acquired pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI), as well as additional ...

A new study from the University of Minnesota Medical School demonstrated that fecal microbiota transplantation ...

A new study from the University of Minnesota Medical School demonstrated that fecal microbiota transplantation (FMT) can rapidly reverse systemic inflammation and improve survival in patients with ...